losartan and Cardiovascular Diseases studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.

Research Excerpts

Excerpt	Relevance	Reference
"ECG strain was evaluated at baseline and after 1 year of therapy in 7409 hypertensive patients in the LIFE study (Losartan Intervention For End-point reduction in hypertension) treated in a blinded manner with atenolol- or losartan-based regimens."	9.14	Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). ( Dahlöf, B; Devereux, RB; Edelman, JM; Kjeldsen, SE; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M, 2009)
"The Losartan Intervention For Endpoint reduction (LIFE) study was a randomized, doubleblind trial that compared the effects of losartan-based treatment with those of atenolol-based treatment on cardiovascular disease (CVD)-related morbidity and mortality in 9193 patients with hypertension and left-ventricular hypertrophy (LVH)."	9.12	An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. ( Atthobari, J; Boersma, C; Carides, GW; Postma, MJ; Voors, AA, 2007)
"Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events."	9.12	Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Ibsen, H; Lindholm, LH; Lyle, PA; Mogensen, CE; Olsen, MH; Snapinn, SM; Wachtell, K; Wan, Y, 2006)
"We explored the impact of baseline left ventricular hypertrophy (LVH) and losartan treatment on renal and cardiovascular (CV) events in 1,513 patients from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial, which studied the effects of losartan on the progression of renal disease and/or death in patients with type 2 diabetes and nephropathy."	9.11	Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. ( Boner, G; Brenner, BM; Cooper, ME; Crow, RS; de Zeeuw, D; Dickson, T; Kowey, PR; McCarroll, K; Parving, HH; Shahinfar, S, 2005)
" We investigated whether body build was independently associated with higher cardiovascular risk and whether treatment with losartan relative to atenolol influenced the impact of body build on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and on cardiovascular death in patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study."	9.11	Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. ( Beevers, G; Dahlöf, B; de Faire, U; de Simone, G; Devereux, RB; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Palmieri, V; Wachtell, K, 2005)
"As part of the Losartan Intervention For End point reduction in hypertension (LIFE) study, 342 hypertensive patients with AF and LV hypertrophy were assigned to losartan- or atenolol-based therapy for 1,471 patient-years of follow-up."	9.11	Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Aurup, P; Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Rokkedal, J; Slotwiner, DJ; Wachtell, K, 2005)
"8 years of antihypertensive treatment were related to changes in risk in 8206 patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study."	9.11	Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2005)
" We measured the QRS duration and QT intervals from the baseline 12-lead electrocardiograms in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study, which included hypertensive patients with electrocardiographic evidence of left ventricular hypertrophy randomized to either losartan-based or atenolol-based treatment to lower blood pressure."	9.11	QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Jern, S; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M, 2004)
"We studied the impact of smoking in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke and myocardial infarction in hypertensives with left ventricular hypertrophy."	9.11	Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004)
"The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study was conducted between 1995 and 2001 to compare the incidence of cardiovascular morbidity and mortality with losartan- or atenolol-based treatment in 9193 patients aged 55 to 80 years with hypertension and left ventricular hypertrophy."	9.10	An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Devereux, RB; Fyhrquist, F; Kjeldsen, SE; Kristianson, K; Lindholm, LH; Lyle, PA; Nieminen, MS; Snapinn, SM, 2003)
"As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based treatment."	9.10	Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristiansson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002)
"To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH)."	9.10	Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002)
"Recently, the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study demonstrated the benefit of losartan in reducing renal outcomes in patients with type 2 diabetes and proteinuria."	9.10	Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study. ( Ahmed, T; Brenner, BM; Dickson, TZ; Ramjit, D; Shahinfar, S; Smith, RD; Zhang, Z, 2002)
" The aim of the LIFE-study was to establish whether treatment with the angiotensin-II AT 1-receptor antagonist, losartan, reduced cardiovascular events more effectively than treatment with the betablocker atenolol in patients with hypertension and left ventricular hypertrophy."	9.10	[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Pedersen, OL, 2003)
"Calcitriol is important in nephroprotective strategy in chronic disease of the kidneys (CDK)."	8.87	[The role of D2 vitamin metabolite paricalcitol in nephroprotective strategy in chronic disease of the kidneys]. ( Kozlovskaia, LV; Milovanov, IuS; Milovanova, LIu, 2011)
"00 mmol/L, body mass index 29) of men with mild to moderate hypertension, for irbesartan, the total treatment cost was euro 15,146, for losartan euro 15,696 and for valsartan euro 15,613; the quality-adjusted life years (QALYs) were irbesartan 12."	7.77	Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. ( Ekman, M; Fragoulakis, V; Maniadakis, N; Papagiannopoulou, V; Yfantopoulos, J, 2011)
"We examined lipid levels in the Losartan Intervention For Endpoint reduction in hypertension study and their impact on the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke."	7.75	Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; de Simone, G; Devereux, RB; Fyhrquist, F; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wedel, H, 2009)
"In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the primary composite end point of cardiovascular death, stroke, and myocardial infarction was reduced by losartan versus atenolol in patients with hypertension and left ventricular hypertrophy."	7.73	Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005)
" Both of the losartan-treated groups presented an apparently reduced cardiac hypertrophy but it was only clear in the low-sodium diet group."	7.69	Chronic angiotensin II antagonism with losartan in one-kidney, one clip hypertensive rats: effect on cardiac hypertrophy, urinary sodium and water excretion and the natriuretic system. ( Bonhomme, MC; Diebold, S; Garcia, R, 1996)
"Losartan was very effective in reducing cardiovascular morbidity and mortality as compared to atenolol."	6.71	[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, S; Lindholm, LH; Pedersen, OL, 2003)
"Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class."	6.42	Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Devereux, RB; Lyle, PA, 2004)
"Losartan shows minimal adverse effects and no influence on graft function and biomarkers of graft fibrosis."	5.51	Short-term Effects of Losartan on Cardiovascular Risk and Allograft Injury Biomarkers in Kidney Transplant Recipients. ( Biedunkiewicz, B; Chamienia, A; Dębska-Ślizień, A; Głyda, M; Heleniak, Z; Konopa, J; Kuźmiuk-Glembin, I; Lizakowski, S; Pięta, R; Renke, M; Rutkowski, B; Tylicki, L, 2022)
" atenolol-based treatment in the LIFE study, we tested whether BP variability assessed as SD and range for BP6-24 months measured at 6, 12, 18 and 24 months of treatment was associated with target organ damage (TOD) defined by LVH on ECG and urine albumin/creatinine ratio at 24 months, and predicted the composite endpoint (CEP) of cardiovascular death, nonfatal myocardial infarction (MI) or stroke occurring after 24 months (CEP = 630 events)."	5.20	Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Mancia, G; Okin, PM; Olsen, MH; Rothwell, PM; Vishram, JK; Wachtell, K, 2015)
"8 years' losartan- versus atenolol-based antihypertensive treatment reduced left ventricular hypertrophy and cardiovascular end points, including cardiovascular death and stroke."	5.20	Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study. ( Bang, CN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Hille, DA; Nieminen, MS; Palmieri, V; Papademetriou, V; Roman, MJ; Wachtell, K, 2015)
"8 years of randomized losartan-based or atenolol-based treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy."	5.15	In-treatment stroke volume predicts cardiovascular risk in hypertension. ( Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Lønnebakken, MT; Wachtell, K, 2011)
"The Telmisartan and Losartan Cardiac Evaluation Trial, a multicenter, prospective, randomized, open-labeled, blinded-endpoint trial, was designed to compare the effects of two angiotensin II receptor blockers (ARBs), telmisartan and losartan, on cardiovascular protection in Japanese patients with mild to moderate essential hypertension."	5.15	Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients. ( Hasegawa, H; Kobayashi, Y; Komuro, I; Mizuguchi, T; Namiki, T; Narumi, H; Ohtsuka, M; Takano, H, 2011)
"ECG strain was evaluated at baseline and after 1 year of therapy in 7409 hypertensive patients in the LIFE study (Losartan Intervention For End-point reduction in hypertension) treated in a blinded manner with atenolol- or losartan-based regimens."	5.14	Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). ( Dahlöf, B; Devereux, RB; Edelman, JM; Kjeldsen, SE; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M, 2009)
"Losartan Intervention For Endpoint reduction in hypertension (LIFE) study."	5.12	The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study. ( Brady, WE; Dahlöf, B; Devereux, RB; Fossum, E; Gleim, GW; Hille, DA; Julius, S; Kizer, JR; Kjeldsen, SE; Lyle, PA, 2007)
"The Losartan Intervention For Endpoint reduction (LIFE) study was a randomized, doubleblind trial that compared the effects of losartan-based treatment with those of atenolol-based treatment on cardiovascular disease (CVD)-related morbidity and mortality in 9193 patients with hypertension and left-ventricular hypertrophy (LVH)."	5.12	An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. ( Atthobari, J; Boersma, C; Carides, GW; Postma, MJ; Voors, AA, 2007)
"Thus, losartan may have the possibility to inhibit platelet activation in patients with hypertension independent of blood pressure reduction."	5.12	Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers. ( Andoh, Y; Dong, J; Fujii, S; Furumoto, T; Imagawa, S; Ishimori, N; Ohmura, K; Ohmura, Y; Sato, Y; Tsutsui, H, 2007)
"Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events."	5.12	Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Ibsen, H; Lindholm, LH; Lyle, PA; Mogensen, CE; Olsen, MH; Snapinn, SM; Wachtell, K; Wan, Y, 2006)
"We analyzed data from Reduction in Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL), a double-blind, randomized trial in 1513 type 2 diabetic patients with nephropathy, focusing on the relationship between the prespecified cardiovascular end point (composite) or hospitalization for heart failure and baseline or reduction in albuminuria."	5.11	Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, S; Zhang, Z, 2004)
"Double-blind, randomized, parallel-group study conducted in 1995-2001 among 9193 men and women with hypertension aged 55 through 80 years (mean, 67 years), with electrocardiographic LVH by Cornell voltage-duration product or Sokolow-Lyon voltage criteria and enrolled in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study."	5.11	Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. ( Aurup, P; Dahlöf, B; Devereux, RB; Edelman, JM; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Snapinn, S; Wedel, H, 2004)
"Prospective cohort substudy of the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) randomized clinical trial, conducted from 1995 to 2001."	5.11	Prognostic significance of left ventricular mass change during treatment of hypertension. ( Aurup, P; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Harris, K; Nieminen, MS; Papademetriou, V; Rokkedal, J; Wachtell, K, 2004)
"8 years of antihypertensive treatment were related to changes in risk in 8206 patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study."	5.11	Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2005)
"As part of the Losartan Intervention For End point reduction in hypertension (LIFE) study, 342 hypertensive patients with AF and LV hypertrophy were assigned to losartan- or atenolol-based therapy for 1,471 patient-years of follow-up."	5.11	Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Aurup, P; Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Rokkedal, J; Slotwiner, DJ; Wachtell, K, 2005)
"We studied the impact of smoking in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke and myocardial infarction in hypertensives with left ventricular hypertrophy."	5.11	Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004)
"This post hoc analysis examined whether baseline proteinuria was predictive of cardiovascular outcomes, and whether losartan modifies the risk of cardiovascular outcomes in these patients given its renal-protective effects."	5.11	Losartan and end-organ protection--lessons from the RENAAL study. ( Brenner, BM; Dickson, TZ; Kowey, PR; Shahinfar, S; Zhang, Z, 2005)
" We investigated whether body build was independently associated with higher cardiovascular risk and whether treatment with losartan relative to atenolol influenced the impact of body build on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and on cardiovascular death in patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study."	5.11	Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. ( Beevers, G; Dahlöf, B; de Faire, U; de Simone, G; Devereux, RB; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Palmieri, V; Wachtell, K, 2005)
"We explored the impact of baseline left ventricular hypertrophy (LVH) and losartan treatment on renal and cardiovascular (CV) events in 1,513 patients from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial, which studied the effects of losartan on the progression of renal disease and/or death in patients with type 2 diabetes and nephropathy."	5.11	Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. ( Boner, G; Brenner, BM; Cooper, ME; Crow, RS; de Zeeuw, D; Dickson, T; Kowey, PR; McCarroll, K; Parving, HH; Shahinfar, S, 2005)
" We measured the QRS duration and QT intervals from the baseline 12-lead electrocardiograms in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study, which included hypertensive patients with electrocardiographic evidence of left ventricular hypertrophy randomized to either losartan-based or atenolol-based treatment to lower blood pressure."	5.11	QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Jern, S; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M, 2004)
"Recently, the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study demonstrated the benefit of losartan in reducing renal outcomes in patients with type 2 diabetes and proteinuria."	5.10	Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study. ( Ahmed, T; Brenner, BM; Dickson, TZ; Ramjit, D; Shahinfar, S; Smith, RD; Zhang, Z, 2002)
"As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based treatment."	5.10	Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristiansson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002)
"5 mg of hydrochlorothiazide, in 90 type 2 diabetic patients with microalbuminuria and blood pressure > 130/85 mmHg, receiving losartan 50 mg as initial treatment during 4 weeks."	5.10	Losartan titration versus diuretic combination in type 2 diabetic patients. ( de Pablos-Velasco, PL; Esmatjes, JE; Fernandez-Vega, F; Lopez de la Torre, ML; Pazos Toral, F; Pozuelo, A; Ruilope, LM, 2002)
" The aim of the LIFE-study was to establish whether treatment with the angiotensin-II AT 1-receptor antagonist, losartan, reduced cardiovascular events more effectively than treatment with the betablocker atenolol in patients with hypertension and left ventricular hypertrophy."	5.10	[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Pedersen, OL, 2003)
"Cardiovascular morbidity and mortality are reduced by treatment with the angiotensin II AT(1)-receptor antagonist losartan compared with conventional treatment with the beta-blocker atenolol in patients with hypertension and electrocardiogram-defined left ventricular hypertrophy, many of whom had known vascular disease."	5.10	Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Helle Berg, S; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2003)
"To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH)."	5.10	Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002)
"The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study was conducted between 1995 and 2001 to compare the incidence of cardiovascular morbidity and mortality with losartan- or atenolol-based treatment in 9193 patients aged 55 to 80 years with hypertension and left ventricular hypertrophy."	5.10	An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Devereux, RB; Fyhrquist, F; Kjeldsen, SE; Kristianson, K; Lindholm, LH; Lyle, PA; Nieminen, MS; Snapinn, SM, 2003)
"Calcitriol is important in nephroprotective strategy in chronic disease of the kidneys (CDK)."	4.87	[The role of D2 vitamin metabolite paricalcitol in nephroprotective strategy in chronic disease of the kidneys]. ( Kozlovskaia, LV; Milovanov, IuS; Milovanova, LIu, 2011)
" The following issues are reported in detail: (1) significance of statins, inhibition of platelet aggregation and vitamins in primary and secondary prevention of cardiovascular disease, (2) comparison of the angiotensin receptor blocker losartan and the beta-blocker atenolol in hypertension (LIFE study), (3) magnetic resonance angiography for the detection of coronary stenoses, (4) advantages and disadvantages of operative and interventional coronary revascularization considering elderly patients and sirolimus-eluting stents, and (5) efficacy of glycoprotein IIb/IIIa inhibition and low molecular weight heparin in acute myocardial infarction."	4.82	[From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I]. ( Böhm, M; Fries, R, 2003)
" The LIFE study concluded that losartan is superior compared to atenolol in terms of prevention of cardiovascular morbidity and mortality, the benefit being for CVA without changing the incidence of myocardial infarction."	4.82	[The best of clinical pharmacology in 2002]. ( Ambrosi, P; Andréjak, M; Gayet, JL, 2003)
"In a 16-week study, eplerenone was more effective than placebo or losartan in lowering systolic blood pressure (BP) and diastolic BP in black patients with mild to moderate hypertension."	4.81	Clinical implications of aldosterone blockade. ( Weber, MA, 2002)
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."	4.21	( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022)
"Lead is considered a causative factor for hypertension and other cardiovascular diseases."	3.85	Sub-chronic lead exposure produces β ( Alonso, MJ; Fioresi, M; Salaices, M; Simões, MR; Toscano, CM; Vassallo, DV, 2017)
"Hyperuricemia and angiotensin II (Ang II) may have a pathogenetic role in the development of hypertension and atherosclerosis as well as cardiovascular disease (CVD) and its prognosis."	3.85	Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44/42 MAPK and PDGFRβ. ( Çetin, A; Kırça, M; Oğuz, N; Uzuner, F; Yeşilkaya, A, 2017)
"00 mmol/L, body mass index 29) of men with mild to moderate hypertension, for irbesartan, the total treatment cost was euro 15,146, for losartan euro 15,696 and for valsartan euro 15,613; the quality-adjusted life years (QALYs) were irbesartan 12."	3.77	Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. ( Ekman, M; Fragoulakis, V; Maniadakis, N; Papagiannopoulou, V; Yfantopoulos, J, 2011)
" Thus, the aim of this study was to compare the effects of losartan, angiotensin II type-1 receptor blocker, on systolic (SBP), diastolic (DBP), and mean (MBP) blood pressure, pulse pressure (PP) and heart rate as well as regional haemodynamics, cardiac hypertrophy and biochemical parameters in adult (L(9): 9-month-old) and aged (L(18): 18-month-old) spontaneously hypertensive rats (SHRs)."	3.75	Effects of angiotensin II type-1 receptor blocker losartan on age-related cardiovascular risk in spontaneously hypertensive rats. ( Grujić-Milanović, J; Ivanov, M; Jovović, D; Mihailović-Stanojević, N; Miloradović, Z, 2009)
"We examined lipid levels in the Losartan Intervention For Endpoint reduction in hypertension study and their impact on the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke."	3.75	Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; de Simone, G; Devereux, RB; Fyhrquist, F; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wedel, H, 2009)
" We explored, in a post hoc analysis, whether MetS predicts cardiovascular events in hypertensive patients with electrocardiographic left ventricular hypertrophy (ECG-LVH) in the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study."	3.74	Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. ( Dahlöf, B; de Simone, G; Devereux, RB; Hille, DA; Ibsen, H; Kjeldsen, SE; Lyle, PA; Olsen, MH; Wachtell, K, 2007)
"In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the primary composite end point of cardiovascular death, stroke, and myocardial infarction was reduced by losartan versus atenolol in patients with hypertension and left ventricular hypertrophy."	3.73	Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005)
" Both of the losartan-treated groups presented an apparently reduced cardiac hypertrophy but it was only clear in the low-sodium diet group."	3.69	Chronic angiotensin II antagonism with losartan in one-kidney, one clip hypertensive rats: effect on cardiac hypertrophy, urinary sodium and water excretion and the natriuretic system. ( Bonhomme, MC; Diebold, S; Garcia, R, 1996)
"Optimal cardiovascular prevention after preeclampsia should be further explored."	3.11	Differential effects of renin-angiotensine-aldosteron system inhibition, sympathoinhibition and low sodium diet on blood pressure in women with a history of preeclampsia: A double-blind, placebo-controlled cross-over trial (the PALM study). ( Franx, A; Groenhof, TKJ; Paauw, ND; Spiering, W; Titia Lely, A; Veerbeek, JHW; Verhaar, MC; Zoet, GA, 2022)
"Losartan was very effective in reducing cardiovascular morbidity and mortality as compared to atenolol."	2.71	[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, S; Lindholm, LH; Pedersen, OL, 2003)
"Hemodialysis patients have uremic dyslipidemia, represented by elevated serum intermediate-density lipoprotein cholesterol (IDL-C) levels, and an increased cardiovascular mortality rate."	2.71	Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. ( Furukawa, T; Hayashi, M; Homma, K; Ichihara, A; Kaneshiro, Y; Kanno, Y; Saruta, T; Takemitsu, T; Takenaka, T; Yoshizawa, M, 2005)
"Diabetic nephropathy is the leading cause of end-stage renal disease."	2.70	Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, SM; Zhang, Z, 2001)
"Diabetic nephropathy is the leading cause of end-stage renal disease."	2.70	[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy]. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, SM; Zhang, Z, 2001)
"Losartan was given in maximal tolerance dose (25-100 mg/day)."	2.70	[Effects of long-term therapy with losartan on baroreflex regulation of cardiovascular system]. ( Brodskaia, IS; Gordeeva, MV; Iakovlev, AN; Mamontov, OV; Pushkarev, AA, 2002)
" However, pharmacologic and dosing differences exist among the various ARBs, and these differences can potentially influence their individual effectiveness."	2.46	Comparing angiotensin II receptor blockers on benefits beyond blood pressure. ( Siragy, HM, 2010)
"Losartan is a selective nonpeptite antagonist against type 1 angiotensin II receptors (AT1R), and has been applied in medical treatments of a variety of cardiovascular diseases, including essential hypertension."	2.45	Cardiovascular effects of losartan and its relevant clinical application. ( Hu, Y; Mao, C; Rui, C; Xu, F; Xu, Z; Zhang, L, 2009)
"Thus, the treatment of hypertension and hyperlipidemia associated with hyperuricemia is also important."	2.44	[Other antihyperuricemic agents]. ( Hisatome, I; Igawa, O; Ogino, K, 2008)
"The RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) study was conducted from 1996 to 2001."	2.43	Losartan: lessons learned from the RENAAL study. ( Brenner, BM; Keane, WF; Lyle, PA; Shahinfar, S; Zhang, Z, 2006)
"Proteinuria is a sign of established kidney damage and plays a direct pathogenic role in the progression of renal and cardiovascular disease."	2.43	Time to abandon microalbuminuria? ( Remuzzi, G; Ruggenenti, P, 2006)
"Losartan is a selective non-peptide angiotensin Type 1-receptor blocker (ARB) with unique uricosuric effect, not shared by other ARBs."	2.43	Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade. ( Chiurchiu, C; Parvanova, A; Remuzzi, G; Ruggenenti, P, 2005)
"For patients with type 2 diabetes mellitus (T2DM) and hypertension, an AII receptor blocker (AIIRB) is recommended as the first drug that should be used."	2.42	Advances in the treatment of diabetic renal disease: focus on losartan. ( Rayner, B, 2004)
"Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class."	2.42	Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Devereux, RB; Lyle, PA, 2004)
"Losartan was the first drug in this class to become commercially available."	2.40	Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. ( Burrell, LM; Johnston, CI, 1997)
"Losartan was demonstrated to be an effective antagonist of many AII-induced actions and an effective antihypertensive agent in many animal models of hypertension (HTN)."	2.38	Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy. ( Eberhardt, RT; Frishman, WH; Kang, PM; Kevak, RM, 1993)
" The classic treatment involves the simultaneous dosing of two antiplatelet drugs, aspirin and clopidogrel/prasugrel."	1.72	Development of a DHA-Losartan hybrid as a potent inhibitor of multiple pathway-induced platelet aggregation. ( Choleva, M; Fragopoulou, E; Ganai, AM; Karpoormath, R; Kiriakidi, S; Mavromoustakos, T; Patha, TK; Tsiailanis, AD; Tzakos, AG; Vrettos, EI, 2022)
"Treatment with losartan (0."	1.46	miR-181b regulates vascular stiffness age dependently in part by regulating TGF-β signaling. ( Adachi, H; Berkowitz, DE; Biswas, D; Das, S; Dunkerly-Eyring, B; Flavell, RA; Henao-Mejia, J; Hori, D; Nomura, Y; Santhanam, L; Steenbergen, C; Steppan, J, 2017)
"Losartan treatment prevented tumor-induced loss of muscle mass and in vitro c26 cell proliferation, decreased tumor weight, and attenuated myocardial expression of interleukin-6."	1.42	Losartan treatment attenuates tumor-induced myocardial dysfunction. ( Bicer, S; Clark, Y; Devine, RD; Jing, R; McCarthy, DO; Reiser, PJ; Stevens, SC; Velten, M; Wold, LE; Youtz, DJ, 2015)
"Hypertension is strongly associated with increased risk of subsequent heart failure."	1.35	[Hypertension and the heart]. ( Andersen, NH; Svendsen, TL; Wachtell, K, 2009)

Research

Studies (153)

Authors

Clinical Trials (16)

Trial Overview

Trial Outcomes

Incidence of Same Symptom Stopping Bystolic as Previous Beta Blocker

Number of Participants With Intolerance of Bystolic, Measured by Side Effect(s) That Lead to Discontinuance of Bystolic by the Patient and/or the Physician

Number of Participants With Mild Symptoms

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	12 (7.84)	18.2507
2000's	102 (66.67)	29.6817
2010's	34 (22.22)	24.3611
2020's	5 (3.27)	2.80

Authors	Studies
García, G	1
Rodríguez-Puyol, M	1
Alajarín, R	1
Serrano, I	1
Sánchez-Alonso, P	1
Griera, M	1
Vaquero, JJ	1
Rodríguez-Puyol, D	1
Alvarez-Builla, J	1
Díez-Marqués, ML	1
Tsiailanis, AD	1
Vrettos, EI	1
Choleva, M	1
Kiriakidi, S	1
Ganai, AM	1
Patha, TK	1
Karpoormath, R	1
Mavromoustakos, T	1
Fragopoulou, E	1
Tzakos, AG	1
Zoet, GA	1
Paauw, ND	1
Veerbeek, JHW	1
Groenhof, TKJ	1
Spiering, W	1
Verhaar, MC	1
Franx, A	1
Titia Lely, A	1
Kuźmiuk-Glembin, I	1
Heleniak, Z	1
Pięta, R	1
Głyda, M	1
Lizakowski, S	1
Renke, M	1
Konopa, J	1
Chamienia, A	1
Biedunkiewicz, B	1
Rutkowski, B	1
Tylicki, L	1
Dębska-Ślizień, A	1
Nese, M	1
Riboli, G	1
Brighetti, G	1
Sassi, V	1
Camela, E	1
Caselli, G	1
Sassaroli, S	1
Borlimi, R	1
Aucoin, M	1
Cooley, K	1
Saunders, PR	1
Carè, J	1
Anheyer, D	1
Medina, DN	1
Cardozo, V	1
Remy, D	1
Hannan, N	1
Garber, A	1
Velayos, M	1
Muñoz-Serrano, AJ	1
Estefanía-Fernández, K	1
Sarmiento Caldas, MC	1
Moratilla Lapeña, L	1
López-Santamaría, M	1
López-Gutiérrez, JC	1
Li, J	1
Zhang, J	1
Shen, S	1
Zhang, B	2
Yu, WW	1
Toyoda, H	1
Huang, DQ	1
Le, MH	1
Nguyen, MH	1
Huang, R	1
Zhu, L	1
Wang, J	6
Xue, L	1
Liu, L	2
Yan, X	2
Huang, S	1
Li, Y	6
Xu, T	1
Li, C	2
Ji, F	1
Ming, F	1
Zhao, Y	2
Cheng, J	1
Wang, Y	3
Zhao, H	1
Hong, S	1
Chen, K	2
Zhao, XA	1
Zou, L	1
Sang, D	1
Shao, H	1
Guan, X	1
Chen, X	2
Chen, Y	4
Wei, J	1
Zhu, C	1
Wu, C	1
Moore, HB	1
Barrett, CD	1
Moore, EE	1
Jhunjhunwala, R	1
McIntyre, RC	1
Moore, PK	1
Hajizadeh, N	1
Talmor, DS	1
Sauaia, A	1
Yaffe, MB	1
Liu, C	3
Lin, Y	1
Dong, Y	1
Wu, Y	1
Bao, Y	1
Yan, H	2
Ma, J	1
Fernández-Cuadros, ME	1
Albaladejo-Florín, MJ	1
Álava-Rabasa, S	1
Usandizaga-Elio, I	1
Martinez-Quintanilla Jimenez, D	1
Peña-Lora, D	1
Neira-Borrajo, I	1
López-Muñoz, MJ	1
Rodríguez-de-Cía, J	1
Pérez-Moro, OS	1
Abdallah, M	1
Alsaleh, H	1
Baradwan, A	1
Alfawares, R	1
Alobaid, A	1
Rasheed, A	1
Soliman, I	1
Wendel Garcia, PD	1
Fumeaux, T	1
Guerci, P	1
Heuberger, DM	1
Montomoli, J	2
Roche-Campo, F	1
Schuepbach, RA	1
Hilty, MP	1
Poloni, TE	1
Carlos, AF	1
Cairati, M	1
Cutaia, C	1
Medici, V	1
Marelli, E	1
Ferrari, D	1
Galli, A	1
Bognetti, P	1
Davin, A	1
Cirrincione, A	1
Ceretti, A	1
Cereda, C	1
Ceroni, M	1
Tronconi, L	1
Vitali, S	1
Guaita, A	1
Leeds, JS	1
Raviprakash, V	1
Jacques, T	1
Scanlon, N	1
Cundall, J	1
Leeds, CM	1
Riva, A	1
Gray, EH	1
Azarian, S	1
Zamalloa, A	1
McPhail, MJW	1
Vincent, RP	1
Williams, R	1
Chokshi, S	1
Patel, VC	1
Edwards, LA	1
Alqarawi, W	1
Birnie, DH	1
Golian, M	1
Nair, GM	1
Nery, PB	1
Klein, A	1
Davis, DR	1
Sadek, MM	1
Neilipovitz, D	1
Johnson, CB	1
Green, MS	1
Redpath, C	1
Miller, DC	1
Beamer, P	1
Billheimer, D	1
Subbian, V	1
Sorooshian, A	1
Campbell, BS	1
Mosier, JM	1
Novaretti, JV	1
Astur, DC	1
Cavalcante, ELB	1
Kaleka, CC	1
Amaro, JT	1
Cohen, M	1
Huang, W	1
Li, T	1
Ling, Y	1
Qian, ZP	1
Zhang, YY	1
Huang, D	1
Xu, SB	1
Liu, XH	1
Xia, L	1
Yang, Y	3
Lu, SH	1
Lu, HZ	1
Zhang, R	2
Ma, JX	1
Tang, S	1
Li, CM	1
Wan, J	1
Wang, JF	1
Ma, JQ	1
Luo, JJ	1
Chen, HY	2
Mi, SL	1
Chen, SY	1
Su, YG	1
Ge, JB	1
Milheiro, SA	1
Gonçalves, J	1
Lopes, RMRM	1
Madureira, M	1
Lobo, L	1
Lopes, A	1
Nogueira, F	1
Fontinha, D	1
Prudêncio, M	1
M Piedade, MF	1
Pinto, SN	1
Florindo, PR	1
Moreira, R	1
Castillo-Lora, J	1
Delley, MF	1
Laga, SM	1
Mayer, JM	1
Sutjarit, N	1
Thongon, N	1
Weerachayaphorn, J	1
Piyachaturawat, P	1
Suksamrarn, A	1
Suksen, K	1
Papachristou, DJ	1
Blair, HC	1
Hu, Y	2
Shen, P	1
Zeng, N	1
Wang, L	3
Yan, D	1
Cui, L	1
Yang, K	2
Zhai, C	1
Yang, M	1
Lao, X	1
Sun, J	1
Ma, N	1
Wang, S	1
Ye, W	1
Guo, P	1
Rahimi, S	1
Singh, MP	1
Gupta, J	1
Nakanishi, I	1
Ohkubo, K	1
Shoji, Y	1
Fujitaka, Y	1
Shimoda, K	1
Matsumoto, KI	1
Fukuhara, K	1
Hamada, H	1
van der Boom, T	1
Gruppen, EG	1
Lefrandt, JD	1
Connelly, MA	1
Links, TP	1
Dullaart, RPF	1
Berry, JD	1
Bedlack, R	1
Mathews, D	1
Agnese, W	1
Apple, S	1
Meloncelli, S	1
Divizia, M	1
Germani, G	1
Adefegha, SA	1
Bottari, NB	1
Leal, DB	1
de Andrade, CM	1
Schetinger, MR	1
Martínez-Velasco, A	1
Perez-Ortiz, AC	1
Antonio-Aguirre, B	1
Martínez-Villaseñor, L	1
Lira-Romero, E	1
Palacio-Pastrana, C	1
Zenteno, JC	1
Ramirez, I	1
Zepeda-Palacio, C	1
Mendoza-Velásquez, C	1
Camacho-Ordóñez, A	1
Ortiz Bibriesca, DM	1
Estrada-Mena, FJ	1
Martin, BL	1
Thompson, LC	1
Kim, YH	2
Snow, SJ	1
Schladweiler, MC	1
Phillips, P	1
Harmon, M	1
King, C	1
Richards, J	1
George, I	1
Haykal-Coates, N	1
Gilmour, MI	1
Kodavanti, UP	1
Hazari, MS	1
Farraj, AK	1
Shen, Z	1
Zou, Y	1
Gao, K	1
Lazar, S	1
Wurtzel, JGT	1
Ma, P	1
Goldfinger, LE	1
Vukelic, M	1
Laloo, A	1
Kyttaris, VC	1
Chen, R	1
Chen, J	2
Xun, J	1
Hu, Z	1
Huang, Q	2
Steinhart, C	1
Shen, Y	1
Lu, H	1
Mansuri, A	1
Lokhande, K	1
Kore, S	1
Gaikwad, S	1
Nawani, N	1
Swamy, KV	1
Junnarkar, M	1
Pawar, S	1
Shaheen, MY	1
Basudan, AM	1
Niazy, AA	1
van den Beucken, JJJP	1
Jansen, JA	1
Alghamdi, HS	1
Gao, Q	2
Guo, X	1
Cao, Y	1
Jia, X	1
Xu, S	1
Lu, C	2
Zhu, H	2
Melku, M	1
Abebe, G	1
Teketel, A	1
Asrie, F	1
Yalew, A	1
Biadgo, B	1
Kassa, E	1
Damtie, D	1
Anlay, DZ	1
Ahmed, MFE	1
Ramadan, H	1
Seinige, D	1
Kehrenberg, C	1
Abd El-Wahab, A	1
Volkmann, N	1
Kemper, N	1
Schulz, J	1
Hu, MY	1
Wu, YN	1
McEvoy, MP	1
Wang, YF	1
Cong, WL	1
Liu, LP	1
Li, XX	1
Zhou, CL	1
Chen, WM	1
Wei, KL	1
Tung, SY	1
Shen, CH	1
Chang, TS	1
Yen, CW	1
Hsieh, YY	1
Chiu, WN	1
Hu, JH	1
Lu, SN	1
Hung, CH	1
Alakavuklar, MA	1
Fuqua, C	1
Luo, KL	1
Underwood, RS	1
Greenwald, I	1
Elashiry, MM	1
Elashiry, M	1
Zeitoun, R	1
Elsayed, R	1
Tian, F	1
Saber, SE	1
Elashry, SH	1
Tay, FR	1
Cutler, CW	1
O'Dowd, A	1
Maciel, M	1
Poole, ST	1
Jobling, MG	1
Rollenhagen, JE	1
Woods, CM	1
Sincock, SA	1
McVeigh, AL	1
Gregory, MJ	1
Maves, RC	1
Prouty, MG	1
Holmes, RK	1
Savarino, SJ	1
Mor, MK	1
Palevsky, PM	1
Kaufman, JS	1
Thiessen Philbrook, H	1
Weisbord, SD	1
Parikh, CR	1
John, CM	1
Phillips, NJ	1
Jarvis, GA	1
Zhu, Y	1
Kilburn, S	1
Kapoor, M	1
Chaturvedi, S	1
Shaw, KJ	1
Chaturvedi, V	1
Kong, X	1
Zhang, T	1
Xiao, H	1
Feng, X	1
Tu, H	1
Feng, J	1
Sabet, M	1
Tarazi, Z	1
Griffith, DC	1
Nguyen, F	1
Guan, P	1
Guerrero, DT	1
Kolla, V	1
Naraparaju, K	1
Perry, LM	1
Soberman, D	1
Pressly, BB	1
Alferiev, IS	1
Chorny, M	1
Brodeur, GM	1
Gao, X	2
Cheng, YH	1
Enten, GA	1
DeSantis, AJ	1
Gaponenko, V	1
Majetschak, M	1
Kim, DY	1
Choi, MJ	1
Ko, TK	1
Lee, NH	1
Kim, OH	1
Cheon, HG	1
Cai, H	1
Yip, V	1
Lee, MV	1
Wong, S	1
Saad, O	1
Ma, S	1
Ljumanovic, N	1
Khojasteh, SC	1
Kamath, AV	1
Shen, BQ	1
Cuypers, ML	1
Chanteux, H	1
Gillent, E	1
Bonnaillie, P	1
Saunders, K	1
Beckers, C	1
Delatour, C	1
Dell'Aiera, S	1
Ungell, AL	1
Nicolaï, J	1
Knapp, AK	1
Chen, A	1
Griffin-Nolan, RJ	1
Baur, LE	1
Carroll, CJW	1
Gray, JE	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Short - Medium and Long Term Blood Pressure Variability in Essential Hypertensive Patients Treated With Nifedipine GITS or Ramipril - a Randomized Trial[NCT02499822]	Phase 4	168 participants (Actual)	Interventional	2015-10-31	Completed
A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260]	Phase 3	496 participants (Actual)	Interventional	1995-06-30	Completed
[NCT00530595]		0 participants	Interventional		Completed
Effect of Nighttime Valsartan on Prognosis of Nocturnal Hypertension Patients Undergoing Maintenance Hemodialysis[NCT03594825]	Phase 4	68 participants (Anticipated)	Interventional	2018-11-30	Not yet recruiting
Fixed Combination for Lipid and Blood Pressure Control. Randomized Cross-over Study[NCT03047538]	Phase 4	0 participants (Actual)	Interventional	2017-09-01	Withdrawn (stopped due to Insufficient funds)
Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy[NCT02921321]		100 participants (Anticipated)	Observational	2014-01-31	Active, not recruiting
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy[NCT00308347]	Phase 3	1,513 participants (Actual)	Interventional	1996-05-31	Completed
Characterization of Myocardial Interstitial Fibrosis and Cardiomyocyte Hypertrophy by Cardiac MRI In Heart Failure: Implication on Early Remodeling and on the Transition to Heart Failure[NCT03084679]		90 participants (Anticipated)	Interventional	2017-11-01	Recruiting
Alternative in Beta Blocker Intolerance; the ABBI Trial[NCT00893984]	Phase 4	6 participants (Actual)	Interventional	2009-05-31	Terminated (stopped due to Lack of patient recruitment)
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705]	Phase 4	102 participants (Actual)	Interventional	2012-08-31	Completed
Glucose Optimisation With Angiotensin II Antagonist Losartan in Patients With Hypertension and Other Risk Factors for Metabolic Syndrome (GOAAL)[NCT00237588]	Phase 4	25 participants	Interventional	2004-12-31	Completed
Open, Randomized, Unicenter Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease[NCT04626323]	Phase 2	60 participants (Anticipated)	Interventional	2021-05-25	Recruiting
SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)[NCT05037695]	Phase 4	40 participants (Anticipated)	Interventional	2021-07-21	Recruiting
Determinants of Diabetic Nephropathy in American Indians[NCT01878045]		141 participants (Actual)	Observational	2013-11-07	Suspended (stopped due to This study is on a temporary Administrative Hold pending further discussion for NIDDK and Tribal Leadership.)
Improving Outcomes in Atrial Fibrillation Patients Aided by Implantable Cardiac Monitor: Evaluation of Chronic Beta-blocker Use Versus As-needed Pharmacological Rate Control[NCT05745337]	Phase 1	20 participants (Anticipated)	Interventional	2023-02-06	Recruiting
Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349]	Phase 4	105 participants (Actual)	Interventional	2012-05-31	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	Participants (Count of Participants)
Nebivolol	0

Intervention	Participants (Count of Participants)
Nebivolol	0

Mild symptoms include weight gain, edema, and headaches (NCT00893984)
Timeframe: 30 Days

Number of Participants With Termination of Bystolic Stratified by Reason

Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline

Intervention	participants (Number)
Nebivolol	1

Intervention	Participants (Count of Participants)
Nebivolol	0

The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention

HbA1C Levels

Intervention	percentage (Mean)
Insulin Glargine, Metformin, Exenatide	-2.43
Insulin Glargine, Metformin, Prandial Insulin	0.44

% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks

Number of Participants With Hypoglycemia

Intervention	% of HbA1C (Mean)
Insulin Glargine, Metformin, Exenatide	7.1
Insulin Glargine, Metformin, Prandial Insulin	7.2

Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks

Weight Change During Trial

Intervention	Participants (Count of Participants)
Insulin Glargine, Metformin, Exenatide	0
Insulin Glargine, Metformin, Prandial Insulin	0

Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks

Article	Year
Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2 Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;	2022
Reconsidering the Polypill for Management of Cardiovascular Risk Factors in Underserved Patients. Current cardiology reports, 2021, 02-17, Volume: 23, Issue:3 Topics: Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Drug Combinations; Heart Disease Risk	2021
Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials. Journal of the American Society of Hypertension : JASH, 2014, Volume: 8, Issue:5 Topics: Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Chlorthalido	2014
Cardiovascular effects of losartan and its relevant clinical application. Current medicinal chemistry, 2009, Volume: 16, Issue:29 Topics: Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Coronary Vessels; Heart; Losartan	2009
Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both? Future cardiology, 2010, Volume: 6, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive	2010
Comparing angiotensin II receptor blockers on benefits beyond blood pressure. Advances in therapy, 2010, Volume: 27, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardiovascular Dis	2010
[The role of D2 vitamin metabolite paricalcitol in nephroprotective strategy in chronic disease of the kidneys]. Terapevticheskii arkhiv, 2011, Volume: 83, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Calcitriol; Cardiovascular Diseases; Chronic Disease; Ergoc	2011
Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? British journal of clinical pharmacology, 2006, Volume: 62, Issue:6 Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Losartan; Risk Factors; Uric Acid; Xanthine Oxidase	2006
The relationship between lung inflammation and cardiovascular disease. American journal of respiratory and critical care medicine, 2012, Jul-01, Volume: 186, Issue:1 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiovascular Diseas	2012
[What is a good marker for better antihypertensive therapy in diabetic patients when coexisting with hypertension]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 9 Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers;	2002
[Tendency and prospect of the development of new ARBs]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60, Issue:10 Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Human	2002
Clinical implications of aldosterone blockade. American heart journal, 2002, Volume: 144, Issue:5 Suppl Topics: Aldosterone; Antihypertensive Agents; Black People; Blood Pressure; Cardiovascular Diseases; Clinica	2002
[Clinical hypertensiology: analysis of trials completed in 2001-2002]. Kardiologiia, 2002, Volume: 42, Issue:10 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor	2002
[The best of clinical pharmacology in 2002]. Archives des maladies du coeur et des vaisseaux, 2003, Volume: 96 Spec No 1 Topics: Anticholesteremic Agents; Antihypertensive Agents; Azetidines; Cardiovascular Diseases; Ezetimibe; H	2003
[From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I]. Medizinische Klinik (Munich, Germany : 1983), 2003, Apr-15, Volume: 98, Issue:4 Topics: Abciximab; Adult; Age Factors; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; An	2003
Advances in the treatment of diabetic renal disease: focus on losartan. Current medical research and opinion, 2004, Volume: 20, Issue:3 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv	2004
Uric acid: role in cardiovascular disease and effects of losartan. Current medical research and opinion, 2004, Volume: 20, Issue:3 Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Humans; Hyperuri	2004
[Serum uric acid--a cardiovasular risk factor?]. Therapeutische Umschau. Revue therapeutique, 2004, Volume: 61, Issue:9 Topics: Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Humans;	2004
Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:11 Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno	2004
[Treatment of hypertensive patients with impaired glucose tolerance (IGT)]. Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 2 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive	2005
Editorial overview: The 'sartans': is it premature to consider PPARgamma receptor agonism a bonus? Current opinion in investigational drugs (London, England : 2000), 2005, Volume: 6, Issue:3 Topics: Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Cardiovascular Dise	2005
[Uric acid--more deleterious than we thought?]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2005, May-19, Volume: 125, Issue:10 Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Female; H	2005
Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:11 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme	2005
The role of the new beta-blockers in treating cardiovascular disease. American journal of hypertension, 2005, Volume: 18, Issue:12 Pt 2 Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans	2005
Losartan: lessons learned from the RENAAL study. Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cli	2006
Time to abandon microalbuminuria? Kidney international, 2006, Volume: 70, Issue:7 Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers;	2006
[LIFE]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64 Suppl 6 Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Double-Bl	2006
[New therapeutic targets for ACE inhibitors and angiotensin receptor blockers]. Polskie Archiwum Medycyny Wewnetrznej, 2007, Volume: 117, Issue:4 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotens	2007
Pathophysiology of target-organ disease: does angiotensin II remain the key? Journal of clinical hypertension (Greenwich, Conn.), 2007, Volume: 9, Issue:11 Suppl 4 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A	2007
[Other antihyperuricemic agents]. Nihon rinsho. Japanese journal of clinical medicine, 2008, Volume: 66, Issue:4 Topics: Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Gout; Gout	2008
Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy. Journal of clinical pharmacology, 1993, Volume: 33, Issue:11 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiovascular Diseas	1993
Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Cardiovascular drugs and therapy, 1995, Volume: 9, Issue:5 Topics: Aged; Aged, 80 and over; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhi	1995
Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. Journal of human hypertension, 1995, Volume: 9 Suppl 5 Topics: Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cardiovascular	1995
Angiotensin receptors and their therapeutic implications. Annual review of pharmacology and toxicology, 1996, Volume: 36 Topics: Amino Acid Sequence; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Age	1996
[Losartan, an angiotensin II receptor blocker: a new trend in cardiovascular chemotherapy]. Klinicheskaia meditsina, 1996, Volume: 74, Issue:3 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun	1996
Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. Drugs & aging, 1997, Volume: 10, Issue:6 Topics: Aged; Aged, 80 and over; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhi	1997
[Role of the renin-angiotensin system in cardiovascular and renal diseases]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1997, Volume: 109, Issue:5 Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseas	1997
[New therapeutic perspectives associated with the introduction of angiotensin II receptor antagonists]. Polskie Archiwum Medycyny Wewnetrznej, 1997, Volume: 97, Issue:4 Topics: Aged; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Cardiovascular Diseases; Clinical Tria	1997
Angiotensin AT1 receptor antagonism and protection against cardiovascular end-organ damage. Journal of human hypertension, 1998, Volume: 12, Issue:5 Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun	1998
[Angiotensin II receptor antagonists. Clinically significant differences]. Ugeskrift for laeger, 1999, Sep-20, Volume: 161, Issue:38 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases;	1999
Angiotensin II type 1 receptor blockade: a new development in cardiovascular pharmacology. International journal of clinical practice, 1998, Volume: 52, Issue:7 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype	1998
Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications. Postgraduate medicine, 2001, Volume: 109, Issue:4 Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitor	2001
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications. The Canadian journal of cardiology, 2002, Volume: 18 Suppl A Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors;	2002

Article	Year
Differential effects of renin-angiotensine-aldosteron system inhibition, sympathoinhibition and low sodium diet on blood pressure in women with a history of preeclampsia: A double-blind, placebo-controlled cross-over trial (the PALM study). Pregnancy hypertension, 2022, Volume: 27 Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Cross-Over	2022
Short-term Effects of Losartan on Cardiovascular Risk and Allograft Injury Biomarkers in Kidney Transplant Recipients. Transplantation proceedings, 2022, Volume: 54, Issue:4 Topics: Albuminuria; Allografts; Biomarkers; Cardiovascular Diseases; Fibrosis; Heart Disease Risk Factors;	2022
Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2 Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;	2022
Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy. Journal of hypertension, 2015, Volume: 33, Issue:12 Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascu	2015
Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study. Hypertension (Dallas, Tex. : 1979), 2015, Volume: 66, Issue:5 Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol;	2015
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2008, Volume: 52, Issue:3 Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds	2008
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2008, Volume: 52, Issue:3 Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds	2008
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2008, Volume: 52, Issue:3 Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds	2008
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2008, Volume: 52, Issue:3 Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds	2008
Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). Circulation, 2009, Apr-14, Volume: 119, Issue:14 Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diastole; Electrocardiography; Fem	2009
Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: the SANDS trial. Journal of clinical hypertension (Greenwich, Conn.), 2009, Volume: 11, Issue:10 Topics: Aged; Algorithms; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors;	2009
All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. European heart journal, 2010, Volume: 31, Issue:18 Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Cardiovascular Diseases; Cause of Dea	2010
Telomere length and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of human hypertension, 2011, Volume: 25, Issue:12 Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases;	2011
In-treatment stroke volume predicts cardiovascular risk in hypertension. Journal of hypertension, 2011, Volume: 29, Issue:8 Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Follo	2011
Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients. Hypertension research : official journal of the Japanese Society of Hypertension, 2011, Volume: 34, Issue:11 Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Benzimidazoles; Benzoates; Ca	2011
Impact of lower achieved blood pressure on outcomes in hypertensive patients. Journal of hypertension, 2012, Volume: 30, Issue:4 Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases;	2012
Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Journal of hypertension, 2012, Volume: 30, Issue:6 Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Bloc	2012
Randomized Polypill crossover trial in people aged 50 and over. PloS one, 2012, Volume: 7, Issue:7 Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cardiovascular	2012
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA, 2002, Sep-25, Volume: 288, Issue:12 Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human	2002
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA, 2002, Sep-25, Volume: 288, Issue:12 Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human	2002
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA, 2002, Sep-25, Volume: 288, Issue:12 Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human	2002
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA, 2002, Sep-25, Volume: 288, Issue:12 Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human	2002
Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study. Kidney international. Supplement, 2002, Issue:82 Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Creatinine; Diabetes	2002
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]. Ugeskrift for laeger, 2003, Jan-27, Volume: 165, Issue:5 Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Doubl	2003
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]. Ugeskrift for laeger, 2003, Jan-27, Volume: 165, Issue:5 Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabe	2003
An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study. Clinical therapeutics, 2003, Volume: 25, Issue:4 Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cholesterol; Do	2003
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Annals of internal medicine, 2003, Aug-05, Volume: 139, Issue:3 Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihyperten	2003
Reducing CVD risk in type 2 DM. Current diabetes reports, 2003, Volume: 3, Issue:5 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents;	2003
The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney international, 2004, Volume: 65, Issue:3 Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Creatinine; End	2004
QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension (Dallas, Tex. : 1979), 2004, Volume: 43, Issue:5 Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Cause of Death; Death, Sudden, Cardiac; Elec	2004
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation, 2004, Aug-24, Volume: 110, Issue:8 Topics: Aged; Albuminuria; Angina, Unstable; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Cardiovasc	2004
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA, 2004, Nov-17, Volume: 292, Issue:19 Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph	2004
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA, 2004, Nov-17, Volume: 292, Issue:19 Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph	2004
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA, 2004, Nov-17, Volume: 292, Issue:19 Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph	2004
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA, 2004, Nov-17, Volume: 292, Issue:19 Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph	2004
Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA, 2004, Nov-17, Volume: 292, Issue:19 Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph	2004
Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA, 2004, Nov-17, Volume: 292, Issue:19 Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph	2004
Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA, 2004, Nov-17, Volume: 292, Issue:19 Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph	2004
Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA, 2004, Nov-17, Volume: 292, Issue:19 Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph	2004
Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA, 2004, Nov-17, Volume: 292, Issue:19 Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph	2004
Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA, 2004, Nov-17, Volume: 292, Issue:19 Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph	2004
Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA, 2004, Nov-17, Volume: 292, Issue:19 Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph	2004
Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA, 2004, Nov-17, Volume: 292, Issue:19 Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph	2004
Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA, 2004, Nov-17, Volume: 292, Issue:19 Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph	2004
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension (Dallas, Tex. : 1979), 2005, Volume: 45, Issue:2 Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cr	2005
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. Journal of the American College of Cardiology, 2005, Mar-01, Volume: 45, Issue:5 Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents;	2005
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. Blood pressure, 2004, Volume: 13, Issue:6 Topics: Aged; Analysis of Variance; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Humans;	2004
Losartan and end-organ protection--lessons from the RENAAL study. Clinical cardiology, 2005, Volume: 28, Issue:3 Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Diabetes Mellitus, Ty	2005
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. Circulation, 2005, Apr-19, Volume: 111, Issue:15 Topics: Aged; Atenolol; Body Mass Index; Body Weight; Cardiovascular Diseases; Female; Humans; Hypertension;	2005
Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:5 Topics: Aged; Anemia; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blo	2005
Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Diabetologia, 2005, Volume: 48, Issue:10 Topics: Aged; Angiotensin II; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Complications; Diab	2005
Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy. American journal of hypertension, 2005, Volume: 18, Issue:11 Topics: Aged; Albuminuria; Antihypertensive Agents; Aortic Valve; Atenolol; Cardiovascular Diseases; Double-	2005
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes care, 2006, Volume: 29, Issue:3 Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cr	2006
The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study. Journal of human hypertension, 2006, Volume: 20, Issue:6 Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Doubl	2006
N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy. Journal of hypertension, 2006, Volume: 24, Issue:8 Topics: Aged; Aged, 80 and over; Albumins; Antihypertensive Agents; Atenolol; Biomarkers; C-Reactive Protein	2006
Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients. Journal of clinical hypertension (Greenwich, Conn.), 2006, Volume: 8, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure	2006
Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors. Journal of human hypertension, 2006, Volume: 20, Issue:11 Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Bloo	2006
Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial. Hypertension (Dallas, Tex. : 1979), 2007, Volume: 49, Issue:2 Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Echocardiograph	2007
Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers. Journal of atherosclerosis and thrombosis, 2007, Volume: 14, Issue:1 Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Aged; Angiotensin II Type 1 Rece	2007
An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. Clinical therapeutics, 2007, Volume: 29, Issue:5 Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Cost-Benefit Analy	2007
Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study). The American journal of cardiology, 2007, Sep-01, Volume: 100, Issue:5 Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih	2007
The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study. Journal of internal medicine, 2007, Volume: 262, Issue:4 Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabetes Compli	2007
Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Cardiovascular drugs and therapy, 1995, Volume: 9, Issue:5 Topics: Aged; Aged, 80 and over; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhi	1995
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy]. Ugeskrift for laeger, 2001, Oct-01, Volume: 163, Issue:40 Topics: Adult; Aged; Angiotensin II; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Ty	2001
Losartan titration versus diuretic combination in type 2 diabetic patients. Journal of hypertension, 2002, Volume: 20, Issue:4 Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Mellit	2002
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (London, England), 2002, Mar-23, Volume: 359, Issue:9311 Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio	2002
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (London, England), 2002, Mar-23, Volume: 359, Issue:9311 Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio	2002
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (London, England), 2002, Mar-23, Volume: 359, Issue:9311 Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio	2002
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (London, England), 2002, Mar-23, Volume: 359, Issue:9311 Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio	2002
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (London, England), 2002, Mar-23, Volume: 359, Issue:9311 Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio	2002
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (London, England), 2002, Mar-23, Volume: 359, Issue:9311 Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio	2002
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (London, England), 2002, Mar-23, Volume: 359, Issue:9311 Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio	2002
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (London, England), 2002, Mar-23, Volume: 359, Issue:9311 Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio	2002
[Effects of long-term therapy with losartan on baroreflex regulation of cardiovascular system]. Klinicheskaia meditsina, 2002, Volume: 80, Issue:3 Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Baroreflex; Cardiovascular Diseases; Humans; Hypert	2002

Article	Year
Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage. Journal of medicinal chemistry, 2009, Nov-26, Volume: 52, Issue:22 Topics: Alcohols; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Blood Pres	2009
Development of a DHA-Losartan hybrid as a potent inhibitor of multiple pathway-induced platelet aggregation. Journal of biomolecular structure & dynamics, 2022, Volume: 40, Issue:24 Topics: Cardiovascular Diseases; Docosahexaenoic Acids; Humans; Losartan; Platelet Aggregation; Platelet Agg	2022
miR-181b regulates vascular stiffness age dependently in part by regulating TGF-β signaling. PloS one, 2017, Volume: 12, Issue:3 Topics: Aging; Angiotensin II; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Cardiovascular Disea	2017
Association of obstructive sleep apnea with arterial stiffness and nondipping blood pressure in patients with hypertension. Journal of clinical hypertension (Greenwich, Conn.), 2017, Volume: 19, Issue:9 Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bloo	2017
Sub-chronic lead exposure produces β Life sciences, 2017, Jul-01, Volume: 180 Topics: Animals; Arterial Pressure; Cardiovascular Diseases; Down-Regulation; Heart Rate; Hexamethonium; Hyp	2017
Alternatives to specific uric acid lowering treatment in gout in patients with cardiovascular disease. BMJ (Clinical research ed.), 2018, Sep-20, Volume: 362 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Calcium Channel Blockers; Cardiov	2018
Impacting Global Health Delivery Through Advocacy: The Case of Losartan. Global heart, 2019, Volume: 14, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Global Health; Humans; Losartan; M	2019
The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockers. Clinical pharmacology and therapeutics, 2014, Volume: 95, Issue:2 Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitu	2014
Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality. Hypertension (Dallas, Tex. : 1979), 2014, Volume: 63, Issue:5 Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl	2014
Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands. Clinical therapeutics, 2014, Mar-01, Volume: 36, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Co	2014
Losartan treatment attenuates tumor-induced myocardial dysfunction. Journal of molecular and cellular cardiology, 2015, Volume: 85 Topics: Adenocarcinoma; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Signaling;	2015
Atherosclerosis, neoatherosclerosis, and vascular disease. European heart journal, 2015, Aug-21, Volume: 36, Issue:32 Topics: Angiotensin II Type 1 Receptor Blockers; Aortic Diseases; Aortic Valve Stenosis; Cardiovascular Dise	2015
The Association of Losartan and Ramipril Therapy With Kidney and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: A Chinese Nation-Wide Cohort Study in Taiwan. Medicine, 2015, Volume: 94, Issue:48 Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors;	2015
Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44/42 MAPK and PDGFRβ. Journal of receptor and signal transduction research, 2017, Volume: 37, Issue:2 Topics: Angiotensin II; Animals; Atherosclerosis; Cardiovascular Diseases; Cell Proliferation; Gene Expressi	2017
Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease. Heart (British Cardiac Society), 2017, Volume: 103, Issue:7 Topics: Administration, Oral; Adult; Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Com	2017
Losartan improves aortic dilatation and cardiovascular disease in mucopolysaccharidosis I. Journal of inherited metabolic disease, 2017, Volume: 40, Issue:3 Topics: Aortic Diseases; Cardiovascular Diseases; Dilatation; Humans; Losartan; Mucopolysaccharidosis I	2017
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. Journal of hypertension, 2009, Volume: 27, Issue:3 Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Cholesterol; Cholesterol, HD	2009
Intensive diabetes management for high-risk patients: how best to deliver? Diabetes care, 2009, Volume: 32, Issue:6 Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Delivery of Health Ca	2009
[Hypertension and the heart]. Ugeskrift for laeger, 2009, Jun-15, Volume: 171, Issue:25 Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrial Fibrillation; Cardiovascula	2009
Effects of angiotensin II type-1 receptor blocker losartan on age-related cardiovascular risk in spontaneously hypertensive rats. General physiology and biophysics, 2009, Volume: 28 Spec No Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Body Weight; Cardiomegaly;	2009
Involvement of the renin-angiotensin system in the development of vascular damage in a rat model of arthritis: effect of angiotensin receptor blockers. Arthritis and rheumatism, 2010, Volume: 62, Issue:5 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Arthritis, Experi	2010
Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. The European journal of health economics : HEPAC : health economics in prevention and care, 2011, Volume: 12, Issue:3 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agen	2011
In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Blood pressure, 2010, Volume: 19, Issue:3 Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Blood Pressure;	2010
Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC cardiovascular disorders, 2010, Jun-09, Volume: 10 Topics: Antihypertensive Agents; Atenolol; Captopril; Cardiovascular Diseases; Cost of Illness; Developing C	2010
Cardiovascular events in subgroups of patients during primary treatment of hypertension with candesartan or losartan. Journal of clinical hypertension (Greenwich, Conn.), 2011, Volume: 13, Issue:3 Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardiovascular Di	2011
Cost-effectiveness analysis of valsartan versus losartan and the effect of switching. Journal of medical economics, 2012, Volume: 15, Issue:2 Topics: Antihypertensive Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Substitution; Fees, Ph	2012
Who is fooling us? Lancet (London, England), 2002, Jul-06, Volume: 360, Issue:9326 Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cardiovascular Di	2002
Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers. Current hypertension reports, 2002, Volume: 4, Issue:5 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents;	2002
Best bang for the buck? Current hypertension reports, 2003, Volume: 5, Issue:1 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents;	2003
[Treatment of hypertension: angiotensin-II antagonists potentially better than beta-blockers in the occurrence of cardiovascular and cerebrovascular damage; the LIFE study in perspective]. Nederlands tijdschrift voor geneeskunde, 2003, Jan-18, Volume: 147, Issue:3 Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agen	2003
More on the LIFE study. Lancet (London, England), 2003, Feb-08, Volume: 361, Issue:9356 Topics: Atenolol; Cardiovascular Diseases; Cause of Death; Conflict of Interest; Drug Industry; Humans; Hype	2003
More on the LIFE study. Lancet (London, England), 2003, Feb-08, Volume: 361, Issue:9356 Topics: Atenolol; Cardiovascular Diseases; Cause of Death; Conflict of Interest; Data Collection; Drug Indus	2003
Losartan vs atenolol in prevention of stroke and cardiovascular disease. JAMA, 2003, Feb-12, Volume: 289, Issue:6 Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten	2003
Losartan vs atenolol in prevention of stroke and cardiovascular disease. JAMA, 2003, Feb-12, Volume: 289, Issue:6 Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten	2003
Summaries for patients. Benefits of losartan in patients with hypertension and left ventricular hypertrophy but no vascular disease. Annals of internal medicine, 2003, Aug-05, Volume: 139, Issue:3 Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihyperten	2003
Angiotensin-converting enzyme inhibitors: optimal management of cardiovascular risk. The American journal of cardiology, 2003, Oct-01, Volume: 92, Issue:7 Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Cardio	2003
[Microalbuminuria is an early marker for increased morbidity and mortality]. Fortschritte der Medizin. Originalien, 2003, Feb-27, Volume: 121 Suppl 1 Topics: Albuminuria; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biom	2003
Hypothetical economic analysis of screening for left ventricular hypertrophy in high-risk normotensive populations. QJM : monthly journal of the Association of Physicians, 2004, Volume: 97, Issue:2 Topics: Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Cost-Benefit Analysis; Echocardiog	2004
Effects of losartan in hypertension without vascular disease. Annals of internal medicine, 2004, Apr-06, Volume: 140, Issue:7 Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Humans; Hyp	2004
Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients. Hypertension (Dallas, Tex. : 1979), 2004, Volume: 44, Issue:1 Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Electrocardiography; Female; Human	2004
The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney international, 2004, Volume: 66, Issue:4 Topics: Antihypertensive Agents; Cardiovascular Diseases; Humans; Hypertension, Renal; Losartan; Uric Acid	2004
Adult hypertension: reducing cardiovascular morbidity and mortality. Prescrire international, 2005, Volume: 14, Issue:75 Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Alcohol Drinking	2005
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. Hypertension (Dallas, Tex. : 1979), 2005, Volume: 45, Issue:4 Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases;	2005
Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy. Hypertension (Dallas, Tex. : 1979), 2005, Volume: 46, Issue:3 Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Animals; At	2005
Blockade of angiotensin II and aging: is the spontaneously hypertensive rat a suitable model? Journal of hypertension, 2006, Volume: 24, Issue:1 Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiovascular Diseases; Cardiovascular Sys	2006
[Kidney protection leads to heart protection, too]. MMW Fortschritte der Medizin, 2006, Aug-17, Volume: 148, Issue:33-34 Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive	2006
Simply removing pressure doesn't work, but youthful drug-taking prevents hereditary mid-life failure. Journal of hypertension, 2007, Volume: 25, Issue:1 Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood	2007
Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age. Journal of hypertension, 2007, Volume: 25, Issue:1 Topics: Age Factors; Aging; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; C	2007
Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. Journal of human hypertension, 2007, Volume: 21, Issue:8 Topics: Aged; Cardiovascular Diseases; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left	2007
Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan. British journal of pharmacology, 2001, Volume: 134, Issue:7 Topics: Adult; Angiotensin Receptor Antagonists; Binding, Competitive; Blood Vessels; Bridged Bicyclo Compou	2001
Chronic angiotensin II antagonism with losartan in one-kidney, one clip hypertensive rats: effect on cardiac hypertrophy, urinary sodium and water excretion and the natriuretic system. Journal of hypertension, 1996, Volume: 14, Issue:1 Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood	1996
Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study. Lancet (London, England), 2002, Jun-22, Volume: 359, Issue:9324 Topics: Antihypertensive Agents; Cardiovascular Diseases; Clinical Trials as Topic; Endpoint Determination;	2002
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study. Lancet (London, England), 2002, Jun-22, Volume: 359, Issue:9324 Topics: Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Melli	2002
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study. Lancet (London, England), 2002, Jun-22, Volume: 359, Issue:9324 Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Heart Rate;	2002
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study. Lancet (London, England), 2002, Jun-22, Volume: 359, Issue:9324 Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Human	2002
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study. Lancet (London, England), 2002, Jun-22, Volume: 359, Issue:9324 Topics: Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Losartan; Treat	2002
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study. Lancet (London, England), 2002, Jun-22, Volume: 359, Issue:9324 Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Disea	2002
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study. Lancet (London, England), 2002, Jun-22, Volume: 359, Issue:9324 Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiovascular Diseases; Diabetes	2002
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study. Lancet (London, England), 2002, Jun-22, Volume: 359, Issue:9324 Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type	2002
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study. Lancet (London, England), 2002, Jun-22, Volume: 359, Issue:9324 Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diure	2002

losartan and Cardiovascular Diseases